No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ATXS Astria Therapeutics Inc
- 8.990
- +0.160+1.81%
Close Jun 18 16:00 ET
- 8.990
- 0.0000.00%
Post 16:18 ET
493.67MMarket Cap-3745P/E (TTM)
9.010High8.760Low403.22KVolume8.850Open8.830Pre Close3.60MTurnover1.29%Turnover RatioLossP/E (Static)54.91MShares16.90052wk High1.81P/B281.37MFloat Cap4.26052wk Low--Dividend TTM31.30MShs Float1017.600Historical High--Div YieldTTM2.83%Amplitude2.360Historical Low8.920Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Astria Therapeutics : Oppenheimer Cuts Target Price to $25 From $29
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
7
$Astria Therapeutics Inc(ATXS.US$ Astria Therapeutics Enters Worldwide Exclusive License Agreement With Ichnos Sciences For An OX40 Portfolio; To Pay Ichnos One-time Upfront License Fee Of $15M, Up To $305M In Milestones
Moomoo 24/7· 17 mins ago![]()
Moomoo 24/7· 17 mins ago
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg